New rules require drugmakers to be clearer about explaining the risks and side effects of prescription drugs. The new ...

Researchers have demonstrated that inebilizumab reduced the risk of symptoms by 87 percent in patients with the rare affliction known as immunoglobulin G4-related disease (IgG4-RD).

Scientists have developed a new technology to efficiently isolate a specific subset of gut bacteria from fecal samples that are recognized by IgA antibodies. These 'IgA-coated' bacteria are associated ...

The first step is to ask each guest about any food allergies, sensitivities and dietary restrictions ahead of time ...

Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria Resubmission includes new pivotal data which confirm ...

Resubmission includes new pivotal data which confirm Dupixent significantly reduced itch and hive activityMore than 300,000 people in the U.S.

A new variant of human mpox has claimed the lives of approximately 5% of people with reported infections in the Democratic Republic of the Congo since 2023, many of them children. Since then, it has ...

An international, phase 3 clinical trial led by investigators at Mass General Brigham could improve the treatment of a rare disease that can cause debilitating symptoms.